- Conditions
- Breast Neoplasms
- Interventions
- Ipatasertib, Paclitaxel, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Fullerton, California • Los Angeles, California • Santa Monica, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified, Ovarian Steroid Cell Tumor
- Interventions
- Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Laboratory Biomarker Analysis, Paclitaxel
- Biological · Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 219
- States / cities
- Anchorage, Alaska • Burbank, California • Sylmar, California + 156 more
- Conditions
- Urinary Tract Infections, Cystitis
- Interventions
- Sulopenem etzadroxil/probenecid, Amoxicillin/clavulanate
- Drug
- Lead sponsor
- Iterum Therapeutics, International Limited
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 167
- States / cities
- Cullman, Alabama • Saraland, Alabama • Sheffield, Alabama + 126 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Adalimumab, Methotrexate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 14
- States / cities
- Fullerton, California • Los Alamitos, California • Aurora, Colorado + 11 more
- Conditions
- Light Chain Deposition Disease, Smoldering Multiple Myeloma
- Interventions
- Clinical Observation, Lenalidomide, Quality-of-Life Assessment
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 601
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Fingolimod, Disease Modifying therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 122
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more
- Conditions
- Myopia
- Interventions
- Atropine Sulfate 0.05% Oph Soln, Placebo
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 664 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Berkeley, California • Fullerton, California + 10 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tarceva, carboplatin, paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 38
- States / cities
- Alhambra, California • Bakersfield, California • Concord, California + 31 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- ABBV-154, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 101
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Faricimab, Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
- Conditions
- Gout
- Interventions
- Febuxostat, Allopurinol
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 258
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
- Conditions
- Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 631
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 678
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
- Conditions
- Breast Neoplasms
- Interventions
- SU011248, Chemotherapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 77
- States / cities
- Corona, California • Fullerton, California • Glendora, California + 59 more
- Conditions
- Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
- Interventions
- Testosterone gel 4.5%, Vehicle gel
- Drug
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Interventions
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 26
- States / cities
- Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, Bepranemab
- Other · Biological
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 40
- States / cities
- Fresno, California • Fullerton, California • Irvine, California + 34 more
- Conditions
- Overweight, Obesity
- Interventions
- zenagamtide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 41
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 36 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- abaloparatide, abaloparatide solid microstructured transdermal system
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
- Conditions
- Intermittent Exotropia
- Interventions
- Vision Therapy
- Other
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Fullerton, California • Stanford, California + 3 more